No Carolina / NY / Florida
Ph: 561.316.3330

MicroTransponder Raises $53M

Appoints New CEO

Summation

  • The company plans to use the funds to commercialize the Vivistim® Paired VNS™ System and establish it as the recommended rehabilitation intervention for stroke survivors working to improve their quality of life through more hand and arm mobility.
  • “The quality of the clinical evidence can lead the therapy to become the standard of care and significantly improve outcomes for stroke survivors.
  • As part of the investment, Casey Tansey of USVP and Bill Harrington of Osage University Partners will join the board of directors.

MicroTransponder, Inc. closed an oversubscribed $53 million Series E funding round led by US Venture Partners (USVP), a multi-stage investment firm. GPG Ventures and Exceller Hunt Ventures return as existing investors alongside new venture investors that include Osage University Partners, Action Potential Venture Capital and The Vertical Group.

The company plans to use the funds to commercialize the Vivistim® Paired VNS™ System and establish it as the recommended rehabilitation intervention for stroke survivors working to improve their quality of life through more hand and arm mobility.

MicroTransponder announced seasoned medical device executive Richard Foust as CEO and Director. “Our investors are energized by MicroTransponder’s vision to enable treatment for the millions of stroke survivors that have ongoing moderate to severe upper limb impairment. Our goal has always been to establish Vivistim Paired VNS as the gold-standard stroke rehabilitation intervention. Today is the day this therapy can help more stroke survivors get back to the daily activities, hobbies and experiences they love,” said Foust.

Foust has over 25 years of strategic leadership in global medical device development and commercialization. He has held executive roles that spanned research and development, marketing, sales and general management at Velano Vascular, Analyte Health, Abbott Vascular, Guidant Corporation, and Perclose.

As part of the investment, Casey Tansey of USVP and Bill Harrington of Osage University Partners will join the board of directors.

“I’m enthusiastic about the MicroTransponder team and the success they have had in building the clinical foundation for Vivistim,” said Tansey. “The quality of the clinical evidence can lead the therapy to become the standard of care and significantly improve outcomes for stroke survivors.”

Vivistim is MicroTransponder’s first FDA-approved use of its novel neuroplasticity-based medical device platform. Vivistim is designed to enhance daily living for people suffering from neurological conditions that impair sensory and motor function.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

- Advertisement -

spot_img

- Advertisement -

Opthea Limited Successfully Completes Placement and Institutional Component of Entitlement Offer Raising A$171.5 million (US$113.2m¹)

“We appreciate the strong support from our shareholders, and from new investors, who share our belief that sozinibercept has the potential to transform patient outcomes with superior vision gains, which continues to be a significant unmet need in wet AMD,” said Frederic Guerard, PharmD, Chief Executive Officer of Opthea Limited.

InduPro Announces $85 Million Series A Financing

InduPro notes the financing will support the advancement of the first expected clinical product candidate targeting cancer tissue based on the proximity of co-targeted pairs, from preclinical development to an expected IND filing in Q4 2025 for a Phase 1 clinical trial. It will also fuel a pipeline of novel bispecific antibodies and antibody drug conjugates (ADCs) that utilizes protein proximity for identification of novel tumor selective target pairings.

Powered By MRP Raises Series A Funding from Aries Capital Partners and Swell Collective

The Series A investment marks a pivotal moment in the company's growth trajectory as it brings together unparalleled expertise and resources to accelerate the company’s expansion plans and market presence.

By using this website you agree to accept Medical Device News Magazine Privacy Policy